e.g. mhealth
Search Results (1 to 10 of 11 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 4 JMIR Cardio
- 2 JMIR Research Protocols
- 1 Interactive Journal of Medical Research
- 1 JMIR Formative Research
- 1 JMIR Medical Informatics
- 1 JMIR mHealth and uHealth
- 1 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Public Health and Surveillance
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Oral anticoagulation therapy (OAC) represents the primary and secondary prevention choice for venous thromboembolism and stroke in patients with nonvalvular atrial fibrillation (NVAF) [1]. As a life-long treatment, OAC is prescribed for various clinical indications, such as heart failure, congenital heart disease, hematological disorders, and peripheral vascular disease, affecting approximately 2% of the Western population.
JMIR Res Protoc 2024;13:e51489
Download Citation: END BibTex RIS
Because the intensity of postsurgical anticoagulation required for a given patient is determined by the nature of cardiac surgery performed, we developed and validated separate models for predicting the warfarin dose required for achieving a discharge INR of 2.0-3.0 in patients undergoing all forms of cardiac surgery other than mechanical mitral valve replacement (ie, prosthetic tissue valve replacement, postsurgical atrial fibrillation, and mechanical aortic valve replacement) and a discharge INR of 2.5-3.5
JMIR Cardio 2023;7:e47262
Download Citation: END BibTex RIS
Telemedicine-Based Management of Oral Anticoagulation Therapy: Systematic Review and Meta-analysis
The quality of oral anticoagulation therapy (OAT), often expressed as time in therapeutic range (TTR), strongly correlates with the incidence of bleeding and thromboembolic events [6].
Different e Health strategies have been implemented to support OAT management. Studies have usually focused on the impact of telemedicine on anticoagulation quality.
J Med Internet Res 2023;25:e45922
Download Citation: END BibTex RIS
Smartphone Apps for Managing Antithrombotic Therapy: Scoping Literature Review
Antithrombotic therapy, including both anticoagulation and platelet aggregation inhibition, is a common therapy for the treatment and prevention of atrial fibrillation (AFib)–related thromboembolic events [1], venous thromboembolism [2], and coronary artery disease [3]. European guidelines recommend oral anticoagulation (OAC) for most patients with AFib and platelet aggregation inhibitors for every patient diagnosed with coronary artery disease without contraindications [3,4].
JMIR Cardio 2022;6(1):e29481
Download Citation: END BibTex RIS
As AF is a major risk factor for stroke, professional societies recommend anticoagulation (AC) in most patients; however, some patients are reluctant to start taking it. Limited health literacy, inaccurate perception of the risk of AF, and lack of trust in physicians contribute to patient refusal, with up to 39.3% (257,415/655,000) of patients remaining off AC across the country [6-8]. Among the patients who start AC, many discontinue treatment, especially after the onset of bleeding or other setbacks.
JMIR Cardio 2021;5(2):e27016
Download Citation: END BibTex RIS
Ultimately, the CPG adhered to a “middle of the road” approach by instituting universal prophylactic weight-based anticoagulation for all patients.
JMIR Med Inform 2021;9(11):e30743
Download Citation: END BibTex RIS
Online Search Trends Influencing Anticoagulation in Patients With COVID-19: Observational Study
The appropriate prescribing of thromboprophylaxis or anticoagulation therapy within 24 hours of admission or 24 hours of a positive COVID-19 result were collected. Three local interventions in the hospital were noted as key events that influenced anticoagulation and thromboprophylaxis guidelines for patients with COVID-19.
JMIR Form Res 2021;5(8):e21817
Download Citation: END BibTex RIS
The latest cardiovascular clinical guidelines already recommend the use of SDM to facilitate an individualized approach to anticoagulation therapy in patients with nonvalvular AF [13].
While the benefits of using PDAs have been validated in Western countries, SDM still remains a novel concept in Asia where paternalism is still the norm [14]. Nevertheless, it has been found that patients in Asia want to be involved in SDM [15,16].
JMIR Cardio 2021;5(2):e23464
Download Citation: END BibTex RIS
Alfalfa consists of a background management system and a remote anticoagulation management system. This remote anticoagulation management system can be divided into a patient terminal called Alfalfa Health Management and a medical terminal called Alfalfa Anticoagulation Guidance.
JMIR Mhealth Uhealth 2021;9(3):e23332
Download Citation: END BibTex RIS
Anticoagulation (AC) is the mainstay of therapy, but many patients are reluctant to start taking anticoagulants [6]. Patients who have a diagnosis of AF generally have a higher risk of stroke than the general population [7]. Even among those who do start AC therapy, many do not persist with the treatment after bleeding or other setbacks. Providers also struggle with balancing the risks and benefits of AC therapy.
JMIR Res Protoc 2021;10(2):e21986
Download Citation: END BibTex RIS